Safety Alerts

Class 4 Medicines Defect Notification: Sandoz Limited, Co-Amoxiclav powder for oral suspension 250/62.5 mg/mL, EL(26)A/46

Published
Source
Alerts and Recalls for Drugs and Medical Devices - General Practice
Imported
5 Nov 2026
Sandoz Limited have informed the MHRA of errors in the dosing table in the Summary of Product Characteristics (SmPC) for Co-amoxiclav 250/62.5 mg/5 ml Powder for Oral Suspension.
View original alert (opens in a new tab)

Important: This alert is gathered automatically for information only. Always refer to the original source and follow your practice’s own clinical governance procedures.

The weekly digest lists every alert published in a week, grouped by source. View the weekly digest

Back to Safety Alerts